DRW Securities’s Lipocine LPCN Stock Holding History

DRW Securities’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-706	Closed	-$41K	–	352
2017 Q4	$41K	Buy	+706	New	+$43.9K	﹤0.01%	452
2016 Q4	–	Sell	-8,580	Closed	-$651K	–	82
2016 Q3	$651K	Hold	8,580	–	–	0.04%	47
2016 Q2	$443K	Buy	+8,580	New	+$1.33M	0.03%	47

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

DRW Securities's LPCN Position: Q1 2018 in Review

DRW Securities sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 706 shares — an estimated $41K sold.

DRW Securities first reported a position in LPCN in Q2 2016 and held it in 3 quarters. The position peaked at $651K in Q3 2016. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

DRW Securities reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
DRW Securities sold 706 Lipocine shares in Q1 2018, an estimated $41K.
DRW Securities first reported a position in Lipocine in Q2 2016 and held it in 3 quarters.
DRW Securities's Lipocine position peaked at $651K in Q3 2016.
27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on DRW Securities's 13F filing for Q1 2018, filed 14 May 2018.